Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma-Reference-Cited by-同舟云学术

Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma

Published:2018-03-09 Issue:9 Volume:53 Page:1116-1123
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Chua Chong Chyn^ORCID,Lim Hui Yin,Chai Khai Li,Ong Jeremy,Sim Shirlene,Wood Colin,Dickinson Michael,Campbell Philip,Hempton Jennifer,King Hayley,Dowsing Claire,Bergin Krystal,Muir Sharon,Gibbs Simon,Grigg Andrew

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0152-2.pdf

Reference20 articles.

1. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28:525–42.

2. Quach H, Joshua D, Ho J, Szer J, Spencer A, Harrison SJ, et al. Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2015;45:94–105.

3. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114:1729–35.

4. Mohty M, Hubel K, Kroger N, Aljurf M, Apperley J, Basak GW, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:865–72.

5. Gertz MA, Dingli D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood. 2014;124:882–90.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolonged infusion time of cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) as a mobilization regimen may improve mobilization efficiency in newly diagnosed multiple myeloma patients: a single center experience;Annals of Medicine;2023-12-12

2. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real‐world single‐centre experience;Internal Medicine Journal;2023-07-23

3. Peripheral Blood Stem Cell Harvesting in Young Children Weighing Less Than 15 Kilograms: A Single-Institute Experience in Taiwan;2023-06-06

4. Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study;Cancers;2023-01-18

5. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF +/−plerixafor vs cyclophosphamide/ GCSF +/−plerixafor;Journal of Clinical Apheresis;2022-02-26